THURSDAY, Oct. 24, 2024 -- For patients with type 2 diabetes (T2D), duodenal recellularization via electroporation therapy (ReCET), which uses pulsed electric fields to induce natural cell death through an apoptosis-like process, is feasible and safe and can prevent the need for insulin therapy when combined with semaglutide, according to a study presented at UEG Week, the annual meeting of United European Gastroenterology, held from Oct.

2024年10月24日，星期四——根据10月10日在欧洲胃肠病学联合会年会UEG Week上发表的一项研究，对于2型糖尿病（T2D）患者，通过电穿孔疗法（ReCET）进行十二指肠再细胞化是可行和安全的，该疗法使用脉冲电场通过凋亡样过程诱导自然细胞死亡，并且可以防止与semaglutide联合使用胰岛素治疗的需要。

4 to 7 in Vienna.Celine Busch, M.D., from Amsterdam University Medical Center, and colleagues presented 24-month results from a single-arm, single-center, first-in-human study conducted in 14 patients with T2D. All patients underwent the ReCET procedure, followed by a two-week isocaloric liquid diet; semaglutide was titrated up to 1 mg/week thereafter.The researchers found that the technical success rate of the ReCET procedure was 100 percent; the median axial treatment length was 12 cm, and median procedure time was 58 minutes.

维也纳4比7。来自阿姆斯特丹大学医学中心的医学博士塞琳·布施及其同事介绍了一项针对14名T2D患者的单臂单中心首次人体研究的24个月结果。所有患者均接受了ReCET手术，然后进行了为期两周的等热量液体饮食；此后，semaglutide滴定至每周1毫克。研究人员发现，ReCET程序的技术成功率为100%；中位数轴向治疗长度为12厘米，中位手术时间为58分钟。

There were no serious adverse events related to the device or severe hypoglycemic events. Thirteen of the patients (93 percent) tolerated the maximum dose of semaglutide. Twelve patients (86 percent) were still not using insulin at six and 12 months, but they had significant improvements in glycemic control and metabolic parameters.

没有与该装置相关的严重不良事件或严重的低血糖事件。13名患者（93%）耐受最大剂量的semaglutide。12名患者（86%）在6个月和12个月时仍不使用胰岛素，但他们在血糖控制和代谢参数方面有显着改善。

All 11 patients who completed the 24-month follow-up remained off insulin with adequate glycemic control.'These findings are very encouraging, suggesting that ReCET is a safe and feasible procedure that, when combined with semaglutide, can effectively eliminate the need for insulin therapy,' Busch said in a statement.Press ReleaseMore InformationWhatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox..

所有完成24个月随访的11名患者均未服用胰岛素，血糖控制良好。”Busch在一份声明中说：“这些发现非常令人鼓舞，表明ReCET是一种安全可行的方法，当与semaglutide联合使用时，可以有效地消除对胰岛素治疗的需求。”。新闻稿更多信息无论您感兴趣的话题是什么，订阅我们的新闻稿，在您的收件箱中获得Drugs.com的最佳信息。。